Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/62942| Title: | The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function |
| Authors: | Patchareeya Amput Christian McSweeney Siripong Palee Arintaya Phrommintikul Siriporn C. Chattipakorn Nipon Chattipakorn |
| Authors: | Patchareeya Amput Christian McSweeney Siripong Palee Arintaya Phrommintikul Siriporn C. Chattipakorn Nipon Chattipakorn |
| Keywords: | Pharmacology, Toxicology and Pharmaceutics |
| Issue Date: | 1-Jan-2019 |
| Abstract: | © 2018 Elsevier Masson SAS Low density lipoprotein cholesterol (LDL-C) is a well-established risk factor for cardiovascular disease. Although there are several developed lipid lowering drugs such as statins and fenofibrates, many patients do not achieve an adequate response. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been developed as a new therapeutic strategy for cholesterol regulation. PCSK9 binds to low density lipoprotein receptors (LDLR) and initiates LDLR degradation, elevating LDL-C. Therefore, PCSK9 inhibition could exert beneficial effects on cardiovascular disease outcomes. This review comprehensively summarizes and discusses the effects of PCSK9 inhibitors on lipid metabolism and cardiovascular function comparatively with current lipid lowering drugs. This review also details essential information regarding the cardiovascular benefits of PCSK9 inhibition which could encourage further clinical studies. |
| URI: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85056208509&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/62942 |
| ISSN: | 19506007 07533322 |
| Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.